Europe’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion favoring the approval of subcutaneous Keytruda, complementing recent FDA authorization. Other treatments receiving favorable opinions include subcutaneous Lunsumio and an insulin icodec/semaglutide combination for diabetes. These regulatory milestones highlight ongoing innovation in drug delivery enhancing patient convenience and adherence across multiple indications.